Microdosing has one of the best stories in the psychedelic world. Take a tiny amount of psilocybin or LSD, too small to trip on, every few days, and feel sharper, calmer and more creative at work. Plenty of people say it works for them. Placebo-controlled trials have found little evidence that microdosing produces lasting improvements in mood, cognition or creativity. Expectation explains much of what people report, although low doses can produce real, short-lived effects on dosing days.
That doesn’t mean microdosers are inventing their experiences. Expectation and ritual can genuinely change how people feel, and the drugs themselves can produce noticeable short-term effects. The harder claim, that repeated microdosing creates lasting improvements in mood, creativity or productivity, has not held up well. Here is what microdosing is, what users report, what the controlled studies found, and what that means for the question this page started with: can microdosing make you more creative and productive at work?
What is microdosing?
Microdosing means repeatedly taking a low, sub-hallucinogenic dose of a psychedelic, intended to produce little or no obvious intoxication. In the controlled studies below, that meant about 10 micrograms of LSD every third day[1] or 0.5 g of dried psilocybin mushrooms[2].
In the largest survey of microdosers, psilocybin was by far the most popular choice: 85% used it, often “stacked” with other supplements such as lion’s mane mushroom or niacin[3]. Schedules vary widely from person to person[3], which is one reason the practice is hard to study. Cannabis has its own version of the idea; our article on microdosing cannabis covers it.
What do microdosers say it does?
The user reports are consistent and enthusiastic. In a 2021 survey of 4,050 microdosers and 4,653 non-microdosers recruited through a mobile app, health and wellness were the most common reasons for microdosing[3]. Among people with mental health concerns, microdosers reported lower levels of depression, anxiety and stress than non-microdosers[3].
These surveys have a built-in limit. The respondents chose to microdose, chose to keep going, and chose to fill in a survey about it. People who tried it and felt nothing may simply stop, and never answer. The authors themselves called for longitudinal studies to test the effects properly[3]. A survey can tell you what microdosers experience. It can’t tell you whether the psychedelic caused it.
What happened when researchers added a placebo?
Since 2021, several controlled studies have compared real microdoses with a placebo, and they tell a consistent story.
The self-blinding study
The most ingenious test was a citizen-science study in which 191 people who already microdosed blinded themselves at home, using their own LSD or psilocybin hidden in capsules alongside identical empty ones, so they didn’t know which week they were taking what[4]. Over four weeks, some took only microdoses, some only placebos, and some a mix.
Everyone improved. Well-being, mindfulness and life satisfaction rose from baseline in the microdose group, but the placebo group improved too, and there was no significant difference between them at four weeks or at the eight-week follow-up[4]. The participants guessed what they had taken 72% of the time, and the small day-to-day differences in mood, energy and creativity were largely explained by those guesses. People who believed they had microdosed felt better in 21 of 22 comparisons, whatever was actually in the capsule[4].
Psilocybin mushrooms in a double-blind trial
One research team gave 34 people starting to microdose either 0.5 g of dried psilocybin mushrooms or a placebo[2]. The mushrooms did change brain activity on EEG, and people noticed acute effects, but only those who correctly guessed they had taken the real thing. The study found no improvement in well-being, creativity or cognition, and a few small changes pointed toward cognitive impairment[2]. The authors concluded that expectation may explain at least some of the benefits microdosers report.
A separate preregistered crossover study had participants microdose psilocybin every third day for three weeks. Compared with placebo, it did not change emotion processing or symptoms of anxiety and depression[5]. Two further double-blind trials in the Netherlands, sharing several of the same researchers and lasting four and eight weeks, found no reliable advantage over placebo for memory, focus, mood or well-being; the psilocybin groups reported more negative bodily sensations[6].
A six-week LSD trial
One of the larger controlled studies gave 80 healthy men either 10 micrograms of LSD or a placebo every third day for six weeks, mostly taken at home[1]. On dosing days, the LSD group did feel more creative, connected, energetic, happy and well, and those day-of effects held up even after the researchers accounted for expectancy[1]. But over the six weeks, there was no lasting change in mood, cognition or personality traits, and the main preregistered hypotheses were not supported[1].
The same trial found one effect no one had predicted: the LSD group slept about 24 minutes longer on the night after each dose, measured by wrist trackers rather than self-report[7].
So does microdosing boost creativity and productivity at work?
No controlled trial has directly shown that microdosing improves workplace productivity. Trials measuring related outcomes, such as creativity, attention, mood and cognition, have generally found no lasting improvement. The self-blinding study found that small acute differences in creativity tracked what people believed they had taken[4]. The mushroom study found no improvement in creativity or cognition[2]. The LSD trial found people felt more creative on dosing days, but no lasting change[1].
There is one narrow exception. A 2025 pooled analysis of three double-blind psilocybin trials with 171 participants found that microdosers produced a higher proportion of original ideas on a divergent-thinking task, though not more ideas overall, and no improvement in convergent, problem-solving thinking[8]. That is a real signal, but a small and specific one.
The closest clinical test of the focus claim comes from ADHD. In a 2025 trial in JAMA Psychiatry, 53 adults with ADHD took 20 micrograms of LSD or a placebo twice a week for six weeks. ADHD symptoms improved in both groups, and LSD was no better than placebo[9]. That result can’t necessarily be generalized to healthy workers, but it doesn’t support the idea that microdosing sharpens focus.
A 2026 umbrella review, pulling together the meta-analyses on microdosing, found no support for cognitive enhancement. The only consistent controlled finding on cognition was a small impairment in cognitive control, the ability to stay on task and override distractions[10]. The reviewers also found that self-reported mood benefits shrink once a placebo is involved[10].
So a microdose may give you a brighter day through some combination of short-lived drug effects, ritual and expectation. It is unlikely to make you measurably more productive, and the pooled evidence suggests that it may slightly impair cognitive control.
These trials measure average effects. They cannot rule out that some people benefit more than others, but researchers have not identified a reliable responder profile or shown that those benefits persist.
What about microdosing for depression?
This is where the research is moving next, and the early results show why placebo control matters. In an open-label phase 2a trial, 19 people with major depression took LSD microdoses of 6 to 20 micrograms twice a week for eight weeks. Clinician-rated depression scores fell by 59.5% and remained lower for up to six months[11]. That sounds encouraging, but there was no placebo group, 15 of the 19 participants were also taking antidepressants, and the study cannot establish how much of the improvement came from LSD[11].
That controlled test has now been run. In preliminary results from a University of Auckland team that includes several of the same researchers, reported in a 2026 conference abstract and presentation, adults with major depression took LSD microdoses or caffeine as an active placebo, in a triple-masked design[12]. The accompanying conference programme reports that 89 participants completed treatment[13]. After eight weeks, depression scores had fallen by 29.9% on LSD and 36.4% on caffeine; LSD was not superior[12]. A full paper has not yet appeared.
Microdosing is a different approach from the single, full, supervised doses tested for depression. For what those larger doses have shown, see our review of psilocybin research for depression and our brief on the phase 3 LSD anxiety trial.
Is microdosing safe?
In the short term, the controlled trials found it fairly well tolerated. In the six-week LSD trial, side effects were mostly mild and no serious adverse events were reported. Feeling jittery was more common on LSD (32.5% versus 7.5% on placebo), and four people on LSD dropped out because of overstimulation or anxiety[1].
The bigger unknown is long-term use. Psilocin (the active form of psilocybin) and LSD activate the serotonin 5-HT2B receptor. Sustained activation of this receptor by some other drugs has been linked to heart-valve fibrosis, raising a theoretical concern about chronic microdosing[14]. No study has yet established that microdosing causes valve disease in people; a 2023 review concluded the risk can’t be quantified because no trial has run long enough with heart scans to check[14]. The 2026 umbrella review agreed that long-term cardiovascular risks remain uncharacterized[10]. For the wider picture on psychedelic side effects, see our brief on adverse effects in a national survey.
These trials also screened who could take part: the Dutch psilocybin trials enrolled healthy volunteers screened for mental health problems[6], and the depression trial excluded anyone with a history of psychotic disorders[12]. Their reassuring short-term safety findings don’t necessarily apply to people outside those limits.
There is also a practical risk: outside trials, nobody knows the dose. Mushroom potency varies, and street LSD is unregulated. In the self-blinding study, researchers had no way to check what people were actually taking[4].
Why does it feel like it works?
Because several things may be happening at once. The drug can produce short-lived effects, while ritual, expectation and paying closer attention to daily habits can also change how people feel. Microdosing also comes with a community that expects good results. The self-blinding study showed that belief alone was enough to lift people’s ratings[4].
That isn’t a reason to sneer at microdosers. It is a reason to be honest about what is doing the work. Full-dose psychedelic experiences are often followed by what people describe as an afterglow, which our article on the psychedelic afterglow explores. Microdoses do not produce the full psychedelic experience from which the classic afterglow is described.
The bottom line
Microdosing is a popular psychedelic claim that has been tested against placebo, and the results are becoming clearer. Low doses can change how people feel on dosing days, one pooled analysis found a narrow creativity signal, and some individuals may experience benefits that small trials do not capture. But lasting improvements in mood, cognition, attention and productivity have not appeared consistently, while expectancy explains much of the reported benefit. The long-term heart question remains theoretical but unresolved. Microdosing is pharmacologically active; it just has not delivered the durable benefits promised for it.
References
- Murphy RJ, Sumner RL, Evans WJ, et al. Acute mood-elevating properties of microdosed LSD in healthy volunteers: a home-administered randomised controlled trial. Biol Psychiatry. 2023.
- Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12.
- Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11.
- Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878.
- Marschall J, Fejer G, Lempe P, et al. Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study. J Psychopharmacol. 2022;36(1):97-113.
- Prochazkova L, Marschall J, Lippelt DP, et al. Cognitive and subjective effects of psilocybin microdosing: results from two double-blind placebo-controlled longitudinal trials. Neuropharmacology. 2026;110722.
- Allen N, Jeremiah A, Murphy R, et al. LSD increases sleep duration the night after microdosing. Transl Psychiatry. 2024;14.
- Prochazkova L, Marschall J, van Elk M, et al. Microdosing psilocybin and its effect on creativity: lessons learned from three double-blind placebo controlled longitudinal trials. Neuropharmacology. 2025.
- Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial. JAMA Psychiatry. 2025;82(6):555-562.
- Özaydın Y, Canlan Özaydın B. Classical psychedelic microdosing, mood, and cognitive function: an umbrella review with narrative synthesis. J Psychopharmacol. 2026.
- Daldegan-Bueno D, Donegan CJ, Sumner RL, et al. LSD microdosing in major depressive disorder: results from an open-label trial. Neuropharmacology. 2026;110762.
- Donegan C, Forsyth A, Sumner R, et al. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder (conference abstract 230). Int J Neuropsychopharmacol. 2026;29(Suppl 1):i11-i12. doi.org/10.1093/ijnp/pyag040.021.
- International Conference on Psychedelic Research. LSD microdosing in major depressive disorder: trend or therapeutic effect? A randomised controlled trial. Presented June 5, 2026.
- Tagen M, Mantuani D, van Heerden L, et al. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J Psychopharmacol. 2023;37(9):876-890.
This article is an educational summary of published research. It is not medical or legal advice. Psilocybin and LSD are controlled substances in most jurisdictions.
Featured image: Psilocybe cubensis mushrooms, by LordToran, via Wikimedia Commons, public domain; cropped and resized.
Last updated: November 2026.
